XML 71 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule Of Components Of (Loss) Income Before Income Tax
The components of loss before income taxes for the following years ended December 31, are as follows: 
Loss Before Income Taxes:202420232022
Europe$(3,708)$(45,835)$(53,684)
U.S.(45,371)(114,942)(57,755)
Total loss before income taxes$(49,079)$(160,777)$(111,439)
Schedule Of Income Tax Provision (Benefit)
The income tax (benefit) provision consists of the following for the years ended December 31:  

 Income Tax (Benefit) Provision:202420232022
Current:  
U.S. - State$— $(661)$— 
Total current— (661)— 
Deferred:  
U.S. - Federal— — 25,896 
U.S. - State(247)160 129 
Total deferred(247)160 26,025 
Income tax (benefit) provision$(247)$(501)$26,025 
Schedule of Effective Income Tax Rate Reconciliation
The reconciliation between income taxes at the statutory rate and the Company’s (benefit) provision for income taxes is as follows for the following years ended December 31: 
 Reconciliation to Effective Income Tax Rate:202420232022
Income tax (benefit) provision - at statutory tax rate$(6,135)$(20,097)$(13,916)
Differences in international tax rates(2,991)(6,635)(9,921)
Return to Provision2,632 856 (101)
Change in valuation allowances4,982 24,332 48,734 
Nondeductible share-based compensation1,444 798 1,424 
Unrealized tax benefits(218)160 258 
State and local taxes (net of federal)778 (5,614)(4,467)
Nondeductible interest expense(848)4,362 4,239 
Orphan drug and R&D tax credit(30)899 — 
Other139 438 (225)
Income tax (benefit) provision - at effective income tax rate$(247)$(501)$26,025 
Summary of Unrecognized Tax Benefits
The following table summarizes the activity related to the Company’s unrecognized tax benefits for the years ended December 31:

 Unrecognized Tax Benefit Activity202420232022
Balance at January 1: $3,035 $3,143 $3,143 
Increases for tax positions of prior years— — — 
Statute of limitations expiration(311)(108)— 
Settlements— — — 
Balance at December 31: $2,724 $3,035 $3,143 
Schedule of Deferred Tax Assets and Liabilities The net deferred tax assets (liabilities) at December 31, 2024 and 2023 resulted from the following temporary differences: 
 Net Deferred Tax Assets and Liabilities: 20242023
Deferred tax assets:  
Net operating loss carryforwards$68,568 $71,051 
Share-based compensation9,791 7,347 
Royalty income9,334 8,378 
Reserves and Other Accruals4,603 — 
Orphan drug and R&D tax credit4,095 4,065 
Capitalized research costs1,568 1,738 
Interest expense carryforward1,460 1,368 
Other1,176 1,322 
Amortization970 1,159 
Gross deferred tax assets101,565 96,428 
Deferred tax liabilities:  
Prepaid expenses— — 
Gross deferred tax liabilities— — 
Less: valuation allowances(101,565)(96,428)
Net deferred tax assets $— $—